ArticleInternational ophthalmology2026
Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo synthesize the available evidence on the relationship between dietary glutamate or glutamatergic metabolism and glaucomatous neurodegeneration, with emphasis on biomarkers, retinal injury mechanisms, and nutritional, antioxidant, or pharmacological strategies with neuroprotective potential.
methodsThis study was conducted as a systematic and bibliometric literature review following the PRISMA 2020 logic of identification, screening, eligibility, and inclusion. Searches were performed in Web of Science, Scopus, and PubMed for studies published in English between 2020 and 2025. The search strategy combined terms related to glaucoma or ocular neurodegeneration, the glutamatergic axis, and biomarkers, mechanisms, or interventions. After screening and full-text assessment, 39 studies were included in the systematic synthesis. Due to methodological heterogeneity, the evidence was synthesized narratively and comparatively, without meta-analysis.
resultsThe included studies were organized into six thematic clusters: metabolomic, transcriptomic, and diagnostic biomarkers; pharmacological and neuroprotective interventions; nutritional, antioxidant, and natural-compound neuroprotection; oxidative stress, mitochondrial dysfunction, and regulated cell death; neuroinflammation and glia-mediated retinal injury; and glutamatergic excitotoxicity and neurotransmitter imbalance. The evidence indicates that glutamate-related mechanisms in glaucoma are mainly associated with endogenous glutamatergic metabolism, excitotoxicity, impaired glutamate clearance, glutamate-glutamine homeostasis, oxidative and nitrosative stress, mitochondrial dysfunction, ferroptosis, neuroinflammation, and retinal ganglion cell vulnerability. None of the 39 included studies directly evaluated dietary glutamate or monosodium glutamate as the main exposure.
conclusionThe available evidence does not support a direct conclusion that dietary glutamate or MSG intake contributes to glaucoma onset or progression. Instead, current findings mainly support an indirect mechanistic relationship between endogenous glutamatergic dysregulation and glaucomatous neurodegeneration. Pharmacological, antioxidant, metabolic, and natural-compound strategies show neuroprotective potential, particularly in experimental models, but clinical and translational studies are still needed to clarify the role of dietary exposure, glutamate-glutamine metabolism, and targeted neuroprotective interventions in glaucoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.